Learn what lerodalcibep is, how this next-generation PCSK9 inhibitor works, and why its once-monthly dosing and potent LDL-C reduction could transform dyslipidemia and ASCVD management in 2025 and beyond.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs